GERMANTOWN, Maryland, and HILDEN, Germany — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its strategic partnership with Exosome Diagnostics Inc. to develop a first-in-class, non-invasive molecular in-vitro diagnostics for use in diagnosing and monitoring patients. The novel blood based diagnostic detects certain mutations of an undisclosed gene associated with […]
Baltimore, MD – BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has received FDA clearance to market the BD MAX™ MRSA XT Assay for use on the fully-automated BD MAX™ System. This is the second assay from BD Diagnostics capable of detecting […]
SAN DIEGO — Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, today announced preliminary highlights of the Company’s 2013 performance, accomplishments and outlined key corporate objectives for 2014. Preliminary 2013 Performance Results (unaudited) • Total revenue of approximately $162 million, showing growth of approximately 81% year-over-year for 2013 […]
Jena (Germany) — After a two year period of development Analytik Jena has launched an innovative technology to enrich and isolate free-circulating DNA. Free-circulating DNA occurs in plasma, serum, and urine, among other things, but only in small fragments and very low concentrations. In order to isolate them, large sample volumes and large quantities of […]
CINCINNATI — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the company’s TRU FLU® assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU® is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens. New strains of […]
SAN DIEGO — Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, announced today its wholly owned subsidiary, Sequenom Laboratories, has signed a national agreement with a leading benefits provider, to provide coverage for the MaterniT21™ PLUS laboratory-developed test (LDT). The addition of this contract brings the number of […]
CARLSBAD, Calif.– Life Technologies (NASDAQ: LIFE) has completed a multi-year license and supply agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, that gives Quest rights to develop molecular tests on the Ion Torrent™ next-generation sequencing platform. Under the agreement, Quest may use the platform and related consumables to independently […]
SAN DIEGO — Illumina, Inc. (NASDAQ:ILMN) today announced it has entered into a multi-year licensing agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, related to the use of Illumina’s next-generation sequencing technology for clinical laboratory testing. Among the terms, Quest will have broad rights to use Illumina’s sequencing and […]
GLOSTRUP, Denmark — Dako, an Agilent Technologies company, announced today it has entered into a master framework agreement with Merck to develop companion diagnostic tests for oncology drugs currently in Merck’s development pipeline. “Dako is relentless in its commitment to fighting cancer, together with our customers and pharma partners,” said Jacob Thaysen, vice president and […]
LAUSANNE, Switzerland — Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the successful achievement of a second development milestone on Spinomix’ two proprietary technologies, namely […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
